Advanced search
Publication Cover
Lung Cancer: Targets and Therapy Volume 15, 2024 - Issue
Submit an article Journal homepage
107
Views
0
CrossRef citations to date
0
Altmetric
COMMENTARY

ATTLAS, IMpower151 and ORIENT-31: Dusting off IMpower150 for Post-Osimertinib in EGFR-Mutated NSCLC?

Jii Bum Lee1 Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of KoreaORCID Iconhttps://orcid.org/0000-0001-5608-3157
ORCID Icon &
Sai-Hong Ignatius Ou2 Division of Hematology-Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California, USA;3 Chao Family Comprehensive Cancer Center, Orange, CA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1764-4975
ORCID Icon
Pages 81-85 | Received 22 Jan 2024, Accepted 09 May 2024, Published online: 24 May 2024

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.